Last reviewed · How we verify
SR750 tablet
At a glance
| Generic name | SR750 tablet |
|---|---|
| Sponsor | Shanghai SIMR Biotechnology Co., Ltd. |
| Modality | Small molecule |
| Phase | Phase 2 |
Approved indications
Common side effects
Key clinical trials
- Efficacy, Safety, and Tolerability of SR750 in Patients With Trigeminal Neuralgia (PHASE2)
- The Pharmacokinetics (PK), Safety, Tolerability of SR750 (Formulation F1) in Healthy Volunteers (PHASE1)
- The Pharmacokinetics (PK), Safety, Tolerability of SR750 in Healthy Volunteers (PHASE1)
- The Safety, Tolerability, and Pharmacokinetics (PK) of SR750 in Healthy Volunteers (PHASE1)
- Comparison of PK After Administration of HCP1201 and Co-administration of Metformin SR 750mg and Rosuvastatin 10mg (PHASE1)
- Comparison of PK After Administration of HCP1201 and Co-administration of Metformin SR 750mg and Rosuvastatin 20mg (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- SR750 tablet CI brief — competitive landscape report
- SR750 tablet updates RSS · CI watch RSS
- Shanghai SIMR Biotechnology Co., Ltd. portfolio CI